JP5341763B2 - ２−アミノカルボニル−ピリジン誘導体 - Google Patents

Info

Publication number

JP5341763B2

JP5341763B2 JP2009531969A JP2009531969A JP5341763B2 JP 5341763 B2 JP5341763 B2 JP 5341763B2 JP 2009531969 A JP2009531969 A JP 2009531969A JP 2009531969 A JP2009531969 A JP 2009531969A JP 5341763 B2 JP5341763 B2 JP 5341763B2

Authority

JP

Japan

Prior art keywords

phenyl

piperazine

carbonyl

amino

butyryl

Prior art date

2006-10-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title abstract description 3
• 230000002792 vascular Effects 0.000 claims abstract description 5
• 150000001875 compounds Chemical class 0.000 claims description 478
• 229910052739 hydrogen Inorganic materials 0.000 claims description 205
• 239000001257 hydrogen Substances 0.000 claims description 205
• -1 hydroxy, hydroxymethyl Chemical group 0.000 claims description 172
• 125000000217 alkyl group Chemical group 0.000 claims description 136
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 109
• 229910052736 halogen Inorganic materials 0.000 claims description 107
• 150000002367 halogens Chemical group 0.000 claims description 107
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 105
• 125000000623 heterocyclic group Chemical group 0.000 claims description 102
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 101
• 125000003545 alkoxy group Chemical group 0.000 claims description 99
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 89
• 125000001424 substituent group Chemical group 0.000 claims description 85
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 82
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 73
• 229910052757 nitrogen Inorganic materials 0.000 claims description 68
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 67
• 125000002947 alkylene group Chemical group 0.000 claims description 64
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 63
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 59
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 47
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 45
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 42
• 239000011737 fluorine Chemical group 0.000 claims description 40
• 229910052731 fluorine Chemical group 0.000 claims description 40
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 39
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
• 229910052740 iodine Inorganic materials 0.000 claims description 36
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 34
• 125000002883 imidazolyl group Chemical group 0.000 claims description 31
• 150000003839 salts Chemical class 0.000 claims description 28
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 27
• 125000004849 alkoxymethyl group Chemical group 0.000 claims description 25
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 23
• 125000003118 aryl group Chemical group 0.000 claims description 21
• 150000002431 hydrogen Chemical class 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 15
• 125000004494 ethyl ester group Chemical group 0.000 claims description 12
• 125000001072 heteroaryl group Chemical group 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• GAFADFDCKOQSFX-QFIPXVFZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(3-hydroxy-3-methylbutyl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(CCC(C)(C)O)=CC(C=2C=CC=CC=2)=N1 GAFADFDCKOQSFX-QFIPXVFZSA-N 0.000 claims description 10
• MTZBKMQNJGVLJX-VWLOTQADSA-N ethyl 4-[(2s)-2-[[4-(3-hydroxy-3-methylbutyl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(CCC(C)(C)O)=CC(C=2C=CC=CC=2)=N1 MTZBKMQNJGVLJX-VWLOTQADSA-N 0.000 claims description 7
• CGISMCWXZOOAIK-UIOOFZCWSA-N ethyl 4-[(2s)-2-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 CGISMCWXZOOAIK-UIOOFZCWSA-N 0.000 claims description 7
• 125000001153 fluoro group Chemical group F* 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• XCTDWWZNPWNEFT-QBGQUKIHSA-N (4s)-4-[(4,6-diphenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonyl-2-methylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound CC1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 XCTDWWZNPWNEFT-QBGQUKIHSA-N 0.000 claims description 5
• QPNBCURWXXUXEF-DEOSSOPVSA-N (4s)-4-[(4,6-diphenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 QPNBCURWXXUXEF-DEOSSOPVSA-N 0.000 claims description 5
• RHXCFGKAHLDDLX-QFIPXVFZSA-N (4s)-4-[(4-butyl-6-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C=1C(CCCC)=CC(C(=O)N[C@@H](CCC(O)=O)C(=O)N2CCN(CC2)C(=O)OCC)=NC=1C1=CC=CC=C1 RHXCFGKAHLDDLX-QFIPXVFZSA-N 0.000 claims description 5
• ONYUNGCCJAEVGH-SFHVURJKSA-N (4s)-4-[(4-chloro-6-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(Cl)=CC(C=2C=CC=CC=2)=N1 ONYUNGCCJAEVGH-SFHVURJKSA-N 0.000 claims description 5
• BYXQKIASCCYOPC-QHCPKHFHSA-N (4s)-4-[(4-cyclopentyloxy-6-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(OC2CCCC2)=CC(C=2C=CC=CC=2)=N1 BYXQKIASCCYOPC-QHCPKHFHSA-N 0.000 claims description 5
• GFOSDJLHZPXBSN-NRFANRHFSA-N (4s)-4-[(4-cyclopropyl-6-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2CC2)=CC(C=2C=CC=CC=2)=N1 GFOSDJLHZPXBSN-NRFANRHFSA-N 0.000 claims description 5
• JDDHYNHCYWINSM-SFHVURJKSA-N (4s)-4-[(6-chloro-4-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(Cl)=N1 JDDHYNHCYWINSM-SFHVURJKSA-N 0.000 claims description 5
• NUVFAJYGOMKURK-FQEVSTJZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(2-hydroxypropan-2-yl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C(C)(C)O)=CC(C=2C=CC=CC=2)=N1 NUVFAJYGOMKURK-FQEVSTJZSA-N 0.000 claims description 5
• UKCKBFFQALLERC-QHCPKHFHSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(4-hydroxypiperidin-1-yl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2CCC(O)CC2)=CC(C=2C=CC=CC=2)=N1 UKCKBFFQALLERC-QHCPKHFHSA-N 0.000 claims description 5
• IVFJKYRAXDEXQB-YADHBBJMSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-[(3r)-3-hydroxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2C[C@H](O)CC2)=CC(C=2C=CC=CC=2)=N1 IVFJKYRAXDEXQB-YADHBBJMSA-N 0.000 claims description 5
• HMAXEALCKDDPBD-GOTSBHOMSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 HMAXEALCKDDPBD-GOTSBHOMSA-N 0.000 claims description 5
• WZJXPTJMTBGJBC-HRTMPFAESA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-[2-(hydroxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2C(C2)CO)=CC(C=2C=CC=CC=2)=N1 WZJXPTJMTBGJBC-HRTMPFAESA-N 0.000 claims description 5
• PLFDVYGVXDPNBL-VNXZQDSDSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-[2-(methoxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2C(C2)COC)=CC(C=2C=CC=CC=2)=N1 PLFDVYGVXDPNBL-VNXZQDSDSA-N 0.000 claims description 5
• JFRQAMKXNUBVCS-DEOSSOPVSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenyl-4-phenylsulfanylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(SC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 JFRQAMKXNUBVCS-DEOSSOPVSA-N 0.000 claims description 5
• LDHBMDPMNYAXQW-NRFANRHFSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenyl-4-propan-2-ylsulfanylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(SC(C)C)=CC(C=2C=CC=CC=2)=N1 LDHBMDPMNYAXQW-NRFANRHFSA-N 0.000 claims description 5
• XAVBSEZQKRGRGO-FQEVSTJZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 XAVBSEZQKRGRGO-FQEVSTJZSA-N 0.000 claims description 5
• FQIQKRJAHZTVST-NRFANRHFSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[[6-phenyl-4-(propan-2-ylamino)pyridine-2-carbonyl]amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(NC(C)C)=CC(C=2C=CC=CC=2)=N1 FQIQKRJAHZTVST-NRFANRHFSA-N 0.000 claims description 5
• XNPQKNXVGFMNQC-VSBJFVJKSA-N 4-[(2s)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[4-[2-(methoxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-3-oxopropyl]benzoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(C=C(C=1)C1C(C1)COC)C=1C=CC=CC=1)CC1=CC=C(C(O)=O)C=C1 XNPQKNXVGFMNQC-VSBJFVJKSA-N 0.000 claims description 5
• 201000010099 disease Diseases 0.000 claims description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
• VDYUAKRIWYIELK-VWLOTQADSA-N ethyl 4-[(2s)-2-[(4,6-diphenylpyridine-2-carbonyl)amino]-3-hydroxypropanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CO)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 VDYUAKRIWYIELK-VWLOTQADSA-N 0.000 claims description 5
• IMYQBKDVCFZKTM-AZKKKJBWSA-N ethyl 4-[(2s)-2-[(4,6-diphenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]-3-methylpiperazine-1-carboxylate Chemical compound CC1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 IMYQBKDVCFZKTM-AZKKKJBWSA-N 0.000 claims description 5
• KMMDGSKYVOJXAE-MHZLTWQESA-N ethyl 4-[(2s)-2-[(4,6-diphenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 KMMDGSKYVOJXAE-MHZLTWQESA-N 0.000 claims description 5
• AFRULBVLAHLVSG-VWLOTQADSA-N ethyl 4-[(2s)-2-[(4-butyl-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C=1C(CCCC)=CC(C(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N2CCN(CC2)C(=O)OCC)=NC=1C1=CC=CC=C1 AFRULBVLAHLVSG-VWLOTQADSA-N 0.000 claims description 5
• GSCMTKFKOWADKG-SANMLTNESA-N ethyl 4-[(2s)-2-[(4-cyclopentyloxy-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(OC2CCCC2)=CC(C=2C=CC=CC=2)=N1 GSCMTKFKOWADKG-SANMLTNESA-N 0.000 claims description 5
• KZNNXLKFQMOMNP-DEOSSOPVSA-N ethyl 4-[(2s)-2-[(4-cyclopropyl-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C2CC2)=CC(C=2C=CC=CC=2)=N1 KZNNXLKFQMOMNP-DEOSSOPVSA-N 0.000 claims description 5
• UDQPAHHZCBJMDI-QHCPKHFHSA-N ethyl 4-[(2s)-2-[[4-(2-hydroxyethylamino)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(NCCO)=CC(C=2C=CC=CC=2)=N1 UDQPAHHZCBJMDI-QHCPKHFHSA-N 0.000 claims description 5
• DMXOWLDCYAWFLN-QHCPKHFHSA-N ethyl 4-[(2s)-2-[[4-(2-hydroxypropan-2-yl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C(C)(C)O)=CC(C=2C=CC=CC=2)=N1 DMXOWLDCYAWFLN-QHCPKHFHSA-N 0.000 claims description 5
• FBJDBQVYSCDSGN-SANMLTNESA-N ethyl 4-[(2s)-2-[[4-(4-hydroxypiperidin-1-yl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2CCC(O)CC2)=CC(C=2C=CC=CC=2)=N1 FBJDBQVYSCDSGN-SANMLTNESA-N 0.000 claims description 5
• DTAYQRWEAGCYIU-STEQJIOHSA-N ethyl 4-[(2s)-2-[[4-[2-(hydroxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C2C(C2)CO)=CC(C=2C=CC=CC=2)=N1 DTAYQRWEAGCYIU-STEQJIOHSA-N 0.000 claims description 5
• UICCYVPSDHUOIV-NXFUPXHFSA-N ethyl 4-[(2s)-2-[[4-[2-(methoxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-3-[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(C=C(C=1)C1C(C1)COC)C=1C=CC=CC=1)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 UICCYVPSDHUOIV-NXFUPXHFSA-N 0.000 claims description 5
• GMPPQAOLFMOLJQ-WNMGUVTHSA-N ethyl 4-[(2s)-2-[[4-[2-(methoxymethyl)cyclopropyl]-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C2C(C2)COC)=CC(C=2C=CC=CC=2)=N1 GMPPQAOLFMOLJQ-WNMGUVTHSA-N 0.000 claims description 5
• UVCHXAJLNIOHBA-DEOSSOPVSA-N ethyl 4-[(2s)-3-cyano-2-[(4,6-diphenylpyridine-2-carbonyl)amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CC#N)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 UVCHXAJLNIOHBA-DEOSSOPVSA-N 0.000 claims description 5
• GDCJFMBFHCAPJA-MHZLTWQESA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenyl-4-phenylsulfanylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(SC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 GDCJFMBFHCAPJA-MHZLTWQESA-N 0.000 claims description 5
• MTJZTLSBLLHONU-QHCPKHFHSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 MTJZTLSBLLHONU-QHCPKHFHSA-N 0.000 claims description 5
• FQQYEPBNPSGNBP-QFIPXVFZSA-N (4s)-5-(4-butoxycarbonylpiperazin-1-yl)-4-[[4-(butylamino)-5-fluoro-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound FC=1C(NCCCC)=CC(C(=O)N[C@@H](CCC(O)=O)C(=O)N2CCN(CC2)C(=O)OCCCC)=NC=1C1=CC=CC=C1 FQQYEPBNPSGNBP-QFIPXVFZSA-N 0.000 claims description 4
• NCSQLEXGSIFVTA-DQEYMECFSA-N (4s)-5-(4-butoxycarbonylpiperazin-1-yl)-4-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 NCSQLEXGSIFVTA-DQEYMECFSA-N 0.000 claims description 4
• WUEYRZBUWIBACI-GOTSBHOMSA-N (4s)-5-(4-butoxycarbonylpiperazin-1-yl)-4-[[5-fluoro-4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=C(F)C(C=2C=CC=CC=2)=N1 WUEYRZBUWIBACI-GOTSBHOMSA-N 0.000 claims description 4
• QEFRJTODCVVAHC-IBGZPJMESA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[(4-methyl-6-phenylpyridine-2-carbonyl)amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C)=CC(C=2C=CC=CC=2)=N1 QEFRJTODCVVAHC-IBGZPJMESA-N 0.000 claims description 4
• HVGUOTMSTMNTTC-SBRHDKPSSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(2-hydroxycyclohexyl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2C(CCCC2)O)=CC(C=2C=CC=CC=2)=N1 HVGUOTMSTMNTTC-SBRHDKPSSA-N 0.000 claims description 4
• OFRWXZNZJUOQMD-NRFANRHFSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(3-hydroxypropyl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(CCCO)=CC(C=2C=CC=CC=2)=N1 OFRWXZNZJUOQMD-NRFANRHFSA-N 0.000 claims description 4
• BRVXRRXTDFQHIV-BOYUCYPVSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(4-hydroxycyclohexyl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2CCC(O)CC2)=CC(C=2C=CC=CC=2)=N1 BRVXRRXTDFQHIV-BOYUCYPVSA-N 0.000 claims description 4
• SGQFBTLJTXZSRH-VWLOTQADSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(4-methoxyphenyl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC(OC)=CC=2)=CC(C=2C=CC=CC=2)=N1 SGQFBTLJTXZSRH-VWLOTQADSA-N 0.000 claims description 4
• XPURPJLTHKOEEK-QFIPXVFZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(furan-3-yl)-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2=COC=C2)=CC(C=2C=CC=CC=2)=N1 XPURPJLTHKOEEK-QFIPXVFZSA-N 0.000 claims description 4
• BIQKKOINAXJTNV-DEOSSOPVSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[6-(2-fluorophenyl)-4-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C(=CC=CC=2)F)=N1 BIQKKOINAXJTNV-DEOSSOPVSA-N 0.000 claims description 4
• JAMAYJCOFZTPGV-VWLOTQADSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[6-(2-methylphenyl)-4-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C(=CC=CC=2)C)=N1 JAMAYJCOFZTPGV-VWLOTQADSA-N 0.000 claims description 4
• IRWPDMXYAABYNB-DEOSSOPVSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[6-(4-fluorophenyl)-4-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC(F)=CC=2)=N1 IRWPDMXYAABYNB-DEOSSOPVSA-N 0.000 claims description 4
• JCGLHSOLYQOHMB-VWLOTQADSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[6-(4-methylphenyl)-4-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC(C)=CC=2)=N1 JCGLHSOLYQOHMB-VWLOTQADSA-N 0.000 claims description 4
• GNYIINRQBKJSTM-NRFANRHFSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(4-phenyl-6-pyrazol-1-ylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(N2N=CC=C2)=N1 GNYIINRQBKJSTM-NRFANRHFSA-N 0.000 claims description 4
• ZIYKZVFOIJOXLZ-NRFANRHFSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenyl-4-pyrazol-1-ylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2N=CC=C2)=CC(C=2C=CC=CC=2)=N1 ZIYKZVFOIJOXLZ-NRFANRHFSA-N 0.000 claims description 4
• PQLLTFALOQNLHK-QFIPXVFZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenyl-4-pyrrolidin-1-ylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(N2CCCC2)=CC(C=2C=CC=CC=2)=N1 PQLLTFALOQNLHK-QFIPXVFZSA-N 0.000 claims description 4
• QJUNWXHDCUPTCR-QFIPXVFZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[(6-phenyl-4-thiophen-3-ylpyridine-2-carbonyl)amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2=CSC=C2)=CC(C=2C=CC=CC=2)=N1 QJUNWXHDCUPTCR-QFIPXVFZSA-N 0.000 claims description 4
• BDQPPNXDFSYZOB-IAXKEJLGSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[[4-(oxolan-3-yloxy)-6-phenylpyridine-2-carbonyl]amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(OC2COCC2)=CC(C=2C=CC=CC=2)=N1 BDQPPNXDFSYZOB-IAXKEJLGSA-N 0.000 claims description 4
• BBHSIQIPHSSBGI-QFIPXVFZSA-N butyl 4-[(2s)-2-[(4-chloro-5-fluoro-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(Cl)=C(F)C(C=2C=CC=CC=2)=N1 BBHSIQIPHSSBGI-QFIPXVFZSA-N 0.000 claims description 4
• WMCDOJNFNGMINJ-LSYYVWMOSA-N butyl 4-[(2s)-2-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](C(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 WMCDOJNFNGMINJ-LSYYVWMOSA-N 0.000 claims description 4
• WIQPBTXRNILOIQ-NSOVKSMOSA-N butyl 4-[(2s)-2-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 WIQPBTXRNILOIQ-NSOVKSMOSA-N 0.000 claims description 4
• CDBUPWAANDIJDJ-AMVUTOCUSA-N butyl 4-[(2s)-2-[[5-fluoro-4-(3-methoxypyrrolidin-1-yl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2CC(CC2)OC)=C(F)C(C=2C=CC=CC=2)=N1 CDBUPWAANDIJDJ-AMVUTOCUSA-N 0.000 claims description 4
• KJOKGYVQTWYFOH-OZXSUGGESA-N butyl 4-[(2s)-3-hydroxy-2-[[4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CO)NC(=O)C1=CC(N2C[C@H](CC2)OC)=CC(C=2C=CC=CC=2)=N1 KJOKGYVQTWYFOH-OZXSUGGESA-N 0.000 claims description 4
• MBBIOTQYLRAMCR-VWLOTQADSA-N ethyl 4-[(2s)-2-[(4,6-diphenylpyridine-2-carbonyl)amino]-3-(2h-tetrazol-5-yl)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(C=C(C=1)C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=NNN=N1 MBBIOTQYLRAMCR-VWLOTQADSA-N 0.000 claims description 4
• MJKOHOJITWLRLL-DEOSSOPVSA-N ethyl 4-[(2s)-2-[(4-cyclopropyl-3-methoxy-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=NC(C=2C=CC=CC=2)=CC(C2CC2)=C1OC MJKOHOJITWLRLL-DEOSSOPVSA-N 0.000 claims description 4
• CJPMDRQYGDYCGC-DEOSSOPVSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenyl-4-propan-2-ylsulfanylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(SC(C)C)=CC(C=2C=CC=CC=2)=N1 CJPMDRQYGDYCGC-DEOSSOPVSA-N 0.000 claims description 4
• BENYJPUKDINIQQ-DEOSSOPVSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[[6-phenyl-4-(propan-2-ylamino)pyridine-2-carbonyl]amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(NC(C)C)=CC(C=2C=CC=CC=2)=N1 BENYJPUKDINIQQ-DEOSSOPVSA-N 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• WRHOJDITGVDOKW-NRFANRHFSA-N (4s)-4-[(4-cyclopropyl-3-methoxy-6-phenylpyridine-2-carbonyl)amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=NC(C=2C=CC=CC=2)=CC(C2CC2)=C1OC WRHOJDITGVDOKW-NRFANRHFSA-N 0.000 claims description 3
• SRHNGMCCGFZQCK-FQEVSTJZSA-N (4s)-4-[[4-(butylamino)-5-fluoro-6-phenylpyridine-2-carbonyl]amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid Chemical compound FC=1C(NCCCC)=CC(C(=O)N[C@@H](CCC(O)=O)C(=O)N2CCN(CC2)C(=O)OCC)=NC=1C1=CC=CC=C1 SRHNGMCCGFZQCK-FQEVSTJZSA-N 0.000 claims description 3
• 239000003085 diluting agent Substances 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• SXAFLELPGSTVCW-SFHVURJKSA-N C(C)(C)(C)OC(=O)CC[C@@H](C(=O)N1CCN(CC1)C(=O)O)NC(=O)C1=NC(=C(C(=C1)Cl)F)C1=CC=CC=C1 Chemical class C(C)(C)(C)OC(=O)CC[C@@H](C(=O)N1CCN(CC1)C(=O)O)NC(=O)C1=NC(=C(C(=C1)Cl)F)C1=CC=CC=C1 SXAFLELPGSTVCW-SFHVURJKSA-N 0.000 claims 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 7
• 208000007536 Thrombosis Diseases 0.000 abstract description 6
• 230000002265 prevention Effects 0.000 abstract description 6
• 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
• 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
• 230000002093 peripheral effect Effects 0.000 abstract description 2
• 229940127424 P2Y12 Receptor Antagonists Drugs 0.000 abstract 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 212
• 239000000543 intermediate Substances 0.000 description 209
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
• 239000002904 solvent Substances 0.000 description 104
• YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 92
• 239000000243 solution Substances 0.000 description 90
• 239000011541 reaction mixture Substances 0.000 description 78
• 125000004432 carbon atom Chemical group C* 0.000 description 68
• 239000012074 organic phase Substances 0.000 description 63
• 239000000203 mixture Substances 0.000 description 62
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
• 239000011734 sodium Substances 0.000 description 42
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
• 239000008346 aqueous phase Substances 0.000 description 26
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
• 238000000034 method Methods 0.000 description 25
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
• 229920006395 saturated elastomer Polymers 0.000 description 24
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 23
• 238000003756 stirring Methods 0.000 description 23
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
• 238000006243 chemical reaction Methods 0.000 description 20
• 238000000746 purification Methods 0.000 description 20
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
• 238000010992 reflux Methods 0.000 description 18
• 125000003831 tetrazolyl group Chemical group 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 17
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 15
• 0 C*(CC1)CC*1C(O)=O Chemical compound C*(CC1)CC*1C(O)=O 0.000 description 13
• 125000006606 n-butoxy group Chemical group 0.000 description 13
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 239000000460 chlorine Chemical group 0.000 description 12
• 238000010168 coupling process Methods 0.000 description 12
• 238000005859 coupling reaction Methods 0.000 description 12
• 238000005160 1H NMR spectroscopy Methods 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 229910052786 argon Inorganic materials 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 239000012043 crude product Substances 0.000 description 10
• 125000004093 cyano group Chemical group *C#N 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• 238000011161 development Methods 0.000 description 9
• LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 9
• 229910052721 tungsten Inorganic materials 0.000 description 9
• BEQUUSCRAKEKQM-UHFFFAOYSA-N 4-chloro-3-fluoropyridine Chemical compound FC1=CN=CC=C1Cl BEQUUSCRAKEKQM-UHFFFAOYSA-N 0.000 description 8
• 239000012267 brine Substances 0.000 description 8
• 230000008878 coupling Effects 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
• GLMODRZPPBZPPB-ZDUSSCGKSA-N (2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 GLMODRZPPBZPPB-ZDUSSCGKSA-N 0.000 description 7
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
• 229910052763 palladium Inorganic materials 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
• HKIRMFBAMLBCKB-UHFFFAOYSA-N 4-chloro-2-methyl-6-phenylpyridine Chemical compound CC1=CC(Cl)=CC(C=2C=CC=CC=2)=N1 HKIRMFBAMLBCKB-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
• 239000003054 catalyst Substances 0.000 description 6
• 238000010438 heat treatment Methods 0.000 description 6
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 238000007254 oxidation reaction Methods 0.000 description 6
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 6
• JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 5
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 5
• 238000006069 Suzuki reaction reaction Methods 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 125000001309 chloro group Chemical group Cl* 0.000 description 5
• 229940126214 compound 3 Drugs 0.000 description 5
• 238000001035 drying Methods 0.000 description 5
• 230000007062 hydrolysis Effects 0.000 description 5
• 238000006460 hydrolysis reaction Methods 0.000 description 5
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
• 239000002480 mineral oil Substances 0.000 description 5
• 235000010446 mineral oil Nutrition 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• DWSBPCLAELVSFD-UHFFFAOYSA-N (2-fluorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC=C1F DWSBPCLAELVSFD-UHFFFAOYSA-N 0.000 description 4
• SXLHAMYMTUEALX-UHFFFAOYSA-N (4-methoxyphenoxy)boronic acid Chemical compound COC1=CC=C(OB(O)O)C=C1 SXLHAMYMTUEALX-UHFFFAOYSA-N 0.000 description 4
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
• 238000001816 cooling Methods 0.000 description 4
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 125000005842 heteroatom Chemical group 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• 239000007800 oxidant agent Substances 0.000 description 4
• 230000001590 oxidative effect Effects 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
• 150000004885 piperazines Chemical class 0.000 description 4
• 238000012746 preparative thin layer chromatography Methods 0.000 description 4
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• 229910052727 yttrium Inorganic materials 0.000 description 4
• VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
• ZEXVWTQBKCZIDH-UHFFFAOYSA-N 2-methyl-6-phenyl-1h-pyridin-4-one Chemical compound N1C(C)=CC(=O)C=C1C1=CC=CC=C1 ZEXVWTQBKCZIDH-UHFFFAOYSA-N 0.000 description 3
• JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 3
• BQADAHRUWDERQF-UHFFFAOYSA-N 4-chloro-6-phenylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC(C=2C=CC=CC=2)=N1 BQADAHRUWDERQF-UHFFFAOYSA-N 0.000 description 3
• TXLINXBIWJYFNR-UHFFFAOYSA-N 4-phenylpyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2C=CC=CC=2)=C1 TXLINXBIWJYFNR-UHFFFAOYSA-N 0.000 description 3
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 239000007868 Raney catalyst Substances 0.000 description 3
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
• 229910000564 Raney nickel Inorganic materials 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 208000024248 Vascular System injury Diseases 0.000 description 3
• 208000012339 Vascular injury Diseases 0.000 description 3
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
• 125000003158 alcohol group Chemical group 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 229960001080 cangrelor Drugs 0.000 description 3
• COWWROCHWNGJHQ-OPKBHZIBSA-J cangrelor tetrasodium Chemical compound [Na+].[Na+].[Na+].[Na+].C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O COWWROCHWNGJHQ-OPKBHZIBSA-J 0.000 description 3
• 125000004181 carboxyalkyl group Chemical group 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 230000006806 disease prevention Effects 0.000 description 3
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
• 229910052698 phosphorus Inorganic materials 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 3
• 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 3
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
• 125000001425 triazolyl group Chemical group 0.000 description 3
• JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 2
• VZOPVKZLLGMDDG-UHFFFAOYSA-N 1-oxido-4-phenylpyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1C1=CC=CC=C1 VZOPVKZLLGMDDG-UHFFFAOYSA-N 0.000 description 2
• RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
• VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 2
• TWXMQDRFBLSXFN-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methyl-1-oxidopyridin-1-ium Chemical compound COC1=C(C)[N+]([O-])=CC=C1Cl TWXMQDRFBLSXFN-UHFFFAOYSA-N 0.000 description 2
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 206010003178 Arterial thrombosis Diseases 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
• 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
• 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• 108010085249 Purinergic P2 Receptors Proteins 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 2
• 208000007718 Stable Angina Diseases 0.000 description 2
• 238000006619 Stille reaction Methods 0.000 description 2
• 239000012317 TBTU Substances 0.000 description 2
• 206010043647 Thrombotic Stroke Diseases 0.000 description 2
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
• 208000007814 Unstable Angina Diseases 0.000 description 2
• 206010047249 Venous thrombosis Diseases 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 229960004676 antithrombotic agent Drugs 0.000 description 2
• 238000007080 aromatic substitution reaction Methods 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 239000010836 blood and blood product Substances 0.000 description 2
• 229940125691 blood product Drugs 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 150000005753 chloropyridines Chemical class 0.000 description 2
• AUNNTHNQWVSPPP-UHFFFAOYSA-N cyclopropyloxyboronic acid Chemical compound OB(O)OC1CC1 AUNNTHNQWVSPPP-UHFFFAOYSA-N 0.000 description 2
• NWROUJFZRNUYMZ-DEOSSOPVSA-N ethyl 4-[(2s)-2-[[4-(3-hydroxypropyl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(CCCO)=CC(C=2C=CC=CC=2)=N1 NWROUJFZRNUYMZ-DEOSSOPVSA-N 0.000 description 2
• WBNDZCRUBNFUQX-DEOSSOPVSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(4-phenyl-6-pyrazol-1-ylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(N2N=CC=C2)=N1 WBNDZCRUBNFUQX-DEOSSOPVSA-N 0.000 description 2
• KOQPUYDOWVDECV-VWLOTQADSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenyl-4-pyrrolidin-1-ylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2CCCC2)=CC(C=2C=CC=CC=2)=N1 KOQPUYDOWVDECV-VWLOTQADSA-N 0.000 description 2
• DOUVHMUACLQZRM-VWLOTQADSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenyl-4-thiophen-3-ylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C2=CSC=C2)=CC(C=2C=CC=CC=2)=N1 DOUVHMUACLQZRM-VWLOTQADSA-N 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 230000023597 hemostasis Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 238000004451 qualitative analysis Methods 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 230000001732 thrombotic effect Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000009278 visceral effect Effects 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• HTGQCLJTWPSFNL-UHFFFAOYSA-N (2-methylphenoxy)boronic acid Chemical compound CC1=CC=CC=C1OB(O)O HTGQCLJTWPSFNL-UHFFFAOYSA-N 0.000 description 1
• FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
• SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
• HLVGFFGIXBJDLD-UHFFFAOYSA-N (4-chloro-3-methoxy-6-phenylpyridin-2-yl)methanol Chemical compound N1=C(CO)C(OC)=C(Cl)C=C1C1=CC=CC=C1 HLVGFFGIXBJDLD-UHFFFAOYSA-N 0.000 description 1
• QDXDLRVMHCMQSL-UHFFFAOYSA-N (4-chloro-3-methoxy-6-phenylpyridin-2-yl)methyl acetate Chemical compound N1=C(COC(C)=O)C(OC)=C(Cl)C=C1C1=CC=CC=C1 QDXDLRVMHCMQSL-UHFFFAOYSA-N 0.000 description 1
• PHBVXHIVWULVNF-UHFFFAOYSA-N (4-fluorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(F)C=C1 PHBVXHIVWULVNF-UHFFFAOYSA-N 0.000 description 1
• DQVXWCCLFKMJTQ-UHFFFAOYSA-N (4-methylphenoxy)boronic acid Chemical compound CC1=CC=C(OB(O)O)C=C1 DQVXWCCLFKMJTQ-UHFFFAOYSA-N 0.000 description 1
• KBCVSUGZOVRTRS-WCSIJFPASA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[[4-(2-oxocyclohexyl)-6-phenylpyridine-2-carbonyl]amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2C(CCCC2)=O)=CC(C=2C=CC=CC=2)=N1 KBCVSUGZOVRTRS-WCSIJFPASA-N 0.000 description 1
• QUBVBRSTVXDQQU-QFIPXVFZSA-N (4s)-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxo-4-[[6-(4-oxocyclohexyl)-2-phenylpyrimidine-4-carbonyl]amino]pentanoic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(C2CCC(=O)CC2)=NC(C=2C=CC=CC=2)=N1 QUBVBRSTVXDQQU-QFIPXVFZSA-N 0.000 description 1
• JLTWHWBUKGOPLH-HJWRWDBZSA-N (z)-4-anilinopent-3-en-2-one Chemical compound CC(=O)\C=C(\C)NC1=CC=CC=C1 JLTWHWBUKGOPLH-HJWRWDBZSA-N 0.000 description 1
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
• VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
• IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
• QPKFVRWIISEVCW-UHFFFAOYSA-N 1-butane boronic acid Chemical compound CCCCB(O)O QPKFVRWIISEVCW-UHFFFAOYSA-N 0.000 description 1
• DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
• MZBZERKDGUOLBE-UHFFFAOYSA-N 1-oxido-2-phenylpyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1C1=CC=CC=C1 MZBZERKDGUOLBE-UHFFFAOYSA-N 0.000 description 1
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
• MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
• KPUJGVVPKGQHPF-UHFFFAOYSA-N 2-methyl-4,6-diphenylpyridine Chemical compound N=1C(C)=CC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 KPUJGVVPKGQHPF-UHFFFAOYSA-N 0.000 description 1
• YJFNCJGKGFCZRM-UHFFFAOYSA-N 2-methyl-6-phenyl-4-pyrazol-1-ylpyridine Chemical compound N=1C(C)=CC(N2N=CC=C2)=CC=1C1=CC=CC=C1 YJFNCJGKGFCZRM-UHFFFAOYSA-N 0.000 description 1
• CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 1
• 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• VNWBCGBVROMFHZ-UHFFFAOYSA-N 3-fluoro-4-(3-methoxypyrrolidin-1-yl)-1-oxido-2-phenylpyridin-1-ium Chemical compound C1C(OC)CCN1C1=CC=[N+]([O-])C(C=2C=CC=CC=2)=C1F VNWBCGBVROMFHZ-UHFFFAOYSA-N 0.000 description 1
• SSTVKXANLHUDJF-UHFFFAOYSA-N 3-fluoro-4-(3-methoxypyrrolidin-1-yl)-1-oxidopyridin-1-ium Chemical compound C1C(OC)CCN1C1=CC=[N+]([O-])C=C1F SSTVKXANLHUDJF-UHFFFAOYSA-N 0.000 description 1
• UIHWTDGFNFXNHL-UHFFFAOYSA-N 3-fluoro-4-(3-methoxypyrrolidin-1-yl)pyridine Chemical compound C1C(OC)CCN1C1=CC=NC=C1F UIHWTDGFNFXNHL-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• PNCROJIUXNQWLJ-UHFFFAOYSA-N 3-phenyl-5-pyrazol-1-ylbenzoic acid Chemical compound C=1C(C(=O)O)=CC(C=2C=CC=CC=2)=CC=1N1C=CC=N1 PNCROJIUXNQWLJ-UHFFFAOYSA-N 0.000 description 1
• ODLVTDCSVYRSPD-UHFFFAOYSA-N 3-tributylstannylprop-2-en-1-ol Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C\CO ODLVTDCSVYRSPD-UHFFFAOYSA-N 0.000 description 1
• WSWSMBKVLHIECU-UHFFFAOYSA-N 4,6-dichloro-3-methoxy-2-methylpyridine Chemical compound COC1=C(C)N=C(Cl)C=C1Cl WSWSMBKVLHIECU-UHFFFAOYSA-N 0.000 description 1
• YISHTFYLAZVESR-UHFFFAOYSA-N 4,6-diphenylpyridine-2-carboxylic acid Chemical compound N=1C(C(=O)O)=CC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 YISHTFYLAZVESR-UHFFFAOYSA-N 0.000 description 1
• VRIGWHSDFGTYSC-AWEZNQCLSA-N 4-[(3s)-3-methoxypyrrolidin-1-yl]-6-phenylpyridine-2-carboxylic acid Chemical compound C1[C@@H](OC)CCN1C1=CC(C(O)=O)=NC(C=2C=CC=CC=2)=C1 VRIGWHSDFGTYSC-AWEZNQCLSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• OSJONKTUKWDIOA-UHFFFAOYSA-N 4-chloro-2-methyl-1-oxidopyridin-1-ium-3-ol Chemical compound CC1=C(O)C(Cl)=CC=[N+]1[O-] OSJONKTUKWDIOA-UHFFFAOYSA-N 0.000 description 1
• JZAJQRQJSKKFAP-UHFFFAOYSA-N 4-chloro-3-fluoro-1-oxido-2-phenylpyridin-1-ium Chemical compound [O-][N+]1=CC=C(Cl)C(F)=C1C1=CC=CC=C1 JZAJQRQJSKKFAP-UHFFFAOYSA-N 0.000 description 1
• NOUWIWISPLZJHT-UHFFFAOYSA-N 4-chloro-3-fluoro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=C(Cl)C(F)=C1 NOUWIWISPLZJHT-UHFFFAOYSA-N 0.000 description 1
• ZLSQLHLIZOLWLT-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methyl-1-oxido-6-phenylpyridin-1-ium Chemical compound C1=C(Cl)C(OC)=C(C)[N+]([O-])=C1C1=CC=CC=C1 ZLSQLHLIZOLWLT-UHFFFAOYSA-N 0.000 description 1
• YUXDUABXROARNN-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methyl-6-phenylpyridine Chemical compound C1=C(Cl)C(OC)=C(C)N=C1C1=CC=CC=C1 YUXDUABXROARNN-UHFFFAOYSA-N 0.000 description 1
• YRUVREKRTJMCSS-UHFFFAOYSA-N 4-chloro-3-methoxy-6-phenylpyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(OC)=C(Cl)C=C1C1=CC=CC=C1 YRUVREKRTJMCSS-UHFFFAOYSA-N 0.000 description 1
• RWCREUXMIVVAAI-UHFFFAOYSA-N 4-chloro-5-fluoro-6-phenylpyridine-2-carbonitrile Chemical compound FC1=C(Cl)C=C(C#N)N=C1C1=CC=CC=C1 RWCREUXMIVVAAI-UHFFFAOYSA-N 0.000 description 1
• HSNSVJGAXUIVDN-UHFFFAOYSA-N 4-chloro-5-fluoro-6-phenylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=C(F)C(C=2C=CC=CC=2)=N1 HSNSVJGAXUIVDN-UHFFFAOYSA-N 0.000 description 1
• BKRVULDPPXVBEG-UHFFFAOYSA-N 4-cyclopentyloxy-2-methyl-6-phenylpyridine Chemical compound C=1C(C=2C=CC=CC=2)=NC(C)=CC=1OC1CCCC1 BKRVULDPPXVBEG-UHFFFAOYSA-N 0.000 description 1
• UAANVFMSVXCFLK-UHFFFAOYSA-N 4-cyclopentyloxy-6-phenylpyridine-2-carboxylic acid Chemical compound C=1C(C=2C=CC=CC=2)=NC(C(=O)O)=CC=1OC1CCCC1 UAANVFMSVXCFLK-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• QDVIVSICXXRMPC-UHFFFAOYSA-N 4-phenyl-6-pyrazol-1-ylpyridine-2-carbonitrile Chemical compound N=1C(C#N)=CC(C=2C=CC=CC=2)=CC=1N1C=CC=N1 QDVIVSICXXRMPC-UHFFFAOYSA-N 0.000 description 1
• GZAQAXFEOGMDHX-UHFFFAOYSA-N 5-fluoro-4-(3-methoxypyrrolidin-1-yl)-6-phenylpyridine-2-carbonitrile Chemical compound C1C(OC)CCN1C1=CC(C#N)=NC(C=2C=CC=CC=2)=C1F GZAQAXFEOGMDHX-UHFFFAOYSA-N 0.000 description 1
• FJPPCBSIEJTZDS-UHFFFAOYSA-N 5-fluoro-4-(3-methoxypyrrolidin-1-yl)-6-phenylpyridine-2-carboxylic acid Chemical compound C1C(OC)CCN1C1=CC(C(O)=O)=NC(C=2C=CC=CC=2)=C1F FJPPCBSIEJTZDS-UHFFFAOYSA-N 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• JIMSKWKYKRHFLG-UHFFFAOYSA-N 6-chloro-4-phenylpyridine-2-carbonitrile Chemical compound N#CC1=NC(Cl)=CC(C=2C=CC=CC=2)=C1 JIMSKWKYKRHFLG-UHFFFAOYSA-N 0.000 description 1
• CPDYSMXQFZKNEN-UHFFFAOYSA-N 6-chloro-4-phenylpyridine-2-carboxylic acid Chemical compound ClC1=NC(C(=O)O)=CC(C=2C=CC=CC=2)=C1 CPDYSMXQFZKNEN-UHFFFAOYSA-N 0.000 description 1
• MIPWEECBIZKMQY-UHFFFAOYSA-N 6-phenyl-4-pyrazol-1-ylpyridine-2-carboxylic acid Chemical compound N=1C(C(=O)O)=CC(N2N=CC=C2)=CC=1C1=CC=CC=C1 MIPWEECBIZKMQY-UHFFFAOYSA-N 0.000 description 1
• BDNQAFNZYVRBAC-UHFFFAOYSA-N 6-phenylpyridine-2-carbonitrile Chemical compound N#CC1=CC=CC(C=2C=CC=CC=2)=N1 BDNQAFNZYVRBAC-UHFFFAOYSA-N 0.000 description 1
• CXOPUGLYEYDAMC-UHFFFAOYSA-N 6-phenylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 CXOPUGLYEYDAMC-UHFFFAOYSA-N 0.000 description 1
• KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
• USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 101710134784 Agnoprotein Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• QFVUSWUNNFKACX-UHFFFAOYSA-N CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC Chemical compound CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC.CCCCCCC QFVUSWUNNFKACX-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• 206010014498 Embolic stroke Diseases 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 108010056764 Eptifibatide Proteins 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
• 206010058991 Hepatic vein occlusion Diseases 0.000 description 1
• 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 241000287462 Phalacrocorax carbo Species 0.000 description 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
• 208000027032 Renal vascular disease Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• WBNUCLPUOSXSNJ-ZDUSSCGKSA-N Sibrafiban Chemical compound C1CC(OCC(=O)OCC)CCN1C(=O)[C@H](C)NC(=O)C1=CC=C(C(=N)NO)C=C1 WBNUCLPUOSXSNJ-ZDUSSCGKSA-N 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000035868 Vascular inflammations Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• RAEQCBUQRWQTCO-NDNWHDOQSA-N [(1s,2s)-2-tributylstannylcyclopropyl]methanol Chemical compound CCCC[Sn](CCCC)(CCCC)[C@H]1C[C@H]1CO RAEQCBUQRWQTCO-NDNWHDOQSA-N 0.000 description 1
• WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• WYVZPKCBWUEEQG-UQKRIMTDSA-N acetic acid;butyl 4-[(2s)-2-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound CC(O)=O.CCCCOC(=O)N1CCN(C(=O)[C@@H](N)CCC(=O)OC(C)(C)C)CC1 WYVZPKCBWUEEQG-UQKRIMTDSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 238000013176 antiplatelet therapy Methods 0.000 description 1
• 239000003698 antivitamin K Substances 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• GROUXWLONUDVBJ-PPHPATTJSA-N butyl 4-[(2s)-2-amino-3-hydroxypropanoyl]piperazine-1-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCOC(=O)N1CCN(C(=O)[C@@H](N)CO)CC1 GROUXWLONUDVBJ-PPHPATTJSA-N 0.000 description 1
• KMEPVAXHVLXJKM-LBPRGKRZSA-N butyl 4-[(2s)-2-amino-3-methylbutanoyl]piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCN(C(=O)[C@@H](N)C(C)C)CC1 KMEPVAXHVLXJKM-LBPRGKRZSA-N 0.000 description 1
• RNDGPEBRLPWRKN-ZDUSSCGKSA-N butyl 4-[(2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCN(C(=O)[C@H](CO)NC(=O)OC(C)(C)C)CC1 RNDGPEBRLPWRKN-ZDUSSCGKSA-N 0.000 description 1
• HGZJRHLEQNTMJS-NRFANRHFSA-N butyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-(phenylmethoxycarbonylamino)pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 HGZJRHLEQNTMJS-NRFANRHFSA-N 0.000 description 1
• SLKNGULILMHDNY-UHFFFAOYSA-N butyl 4-[3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCN(C(=O)C(NC(=O)OC(C)(C)C)C(C)C)CC1 SLKNGULILMHDNY-UHFFFAOYSA-N 0.000 description 1
• GZVCWEXQFYYQRJ-UHFFFAOYSA-N butyl 4-benzylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1CC1=CC=CC=C1 GZVCWEXQFYYQRJ-UHFFFAOYSA-N 0.000 description 1
• NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• AILAQOYFPLQIFN-UHFFFAOYSA-N butyl piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCNCC1 AILAQOYFPLQIFN-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 229960004588 cilostazol Drugs 0.000 description 1
• RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 125000004966 cyanoalkyl group Chemical group 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 238000007257 deesterification reaction Methods 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
• HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
• NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 238000013171 endarterectomy Methods 0.000 description 1
• 229960004468 eptifibatide Drugs 0.000 description 1
• GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• ZHCINJQZDFCSEL-CYBMUJFWSA-N ethyl (3s)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoate Chemical compound CCOC(=O)C[C@@H](C#C)NC(=O)CCC(=O)NC1=CC=C(C(N)=N)C=C1 ZHCINJQZDFCSEL-CYBMUJFWSA-N 0.000 description 1
• LVUYWUXZIJRBFZ-UXMRNZNESA-N ethyl 2-[(2s)-3-[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]-2-(phenylmethoxycarbonylamino)propanoyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1C(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 LVUYWUXZIJRBFZ-UXMRNZNESA-N 0.000 description 1
• VJDOPFARMOLELX-ZDUSSCGKSA-N ethyl 3-[[(3s)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate Chemical compound O=C1[C@@H](NC(=O)NCCC(=O)OCC)CCN1C1=CC=C(C(N)=N)C=C1 VJDOPFARMOLELX-ZDUSSCGKSA-N 0.000 description 1
• RHMXCWDXTCQXSC-IJHRGXPZSA-N ethyl 3-methyl-4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-(phenylmethoxycarbonylamino)pentanoyl]piperazine-1-carboxylate Chemical compound CC1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 RHMXCWDXTCQXSC-IJHRGXPZSA-N 0.000 description 1
• BCRCNSBMXWWOJT-UHFFFAOYSA-N ethyl 3-methylpiperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNC(C)C1 BCRCNSBMXWWOJT-UHFFFAOYSA-N 0.000 description 1
• FIKYIKZFNRACOC-NDEPHWFRSA-N ethyl 4-[(2s)-2-[(4,6-diphenylpyridine-2-carbonyl)amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](COC(C)(C)C)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 FIKYIKZFNRACOC-NDEPHWFRSA-N 0.000 description 1
• KPMPQYUXQFIZAO-QHCPKHFHSA-N ethyl 4-[(2s)-2-[(4-acetyl-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C(C)=O)=CC(C=2C=CC=CC=2)=N1 KPMPQYUXQFIZAO-QHCPKHFHSA-N 0.000 description 1
• DNXNSLWYJRPYRV-NRFANRHFSA-N ethyl 4-[(2s)-2-[(4-chloro-3-methoxy-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=NC(C=2C=CC=CC=2)=CC(Cl)=C1OC DNXNSLWYJRPYRV-NRFANRHFSA-N 0.000 description 1
• BSPYJBULYHJYBH-FQEVSTJZSA-N ethyl 4-[(2s)-2-[(4-chloro-5-fluoro-6-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(Cl)=C(F)C(C=2C=CC=CC=2)=N1 BSPYJBULYHJYBH-FQEVSTJZSA-N 0.000 description 1
• UIKCZVJOBCHOGC-NRFANRHFSA-N ethyl 4-[(2s)-2-[(6-chloro-4-phenylpyridine-2-carbonyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C=2C=CC=CC=2)=CC(Cl)=N1 UIKCZVJOBCHOGC-NRFANRHFSA-N 0.000 description 1
• HAVJYVTWFMPJBF-VWLOTQADSA-N ethyl 4-[(2s)-2-[[4-(1-ethoxyethenyl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C(=C)OCC)=CC(C=2C=CC=CC=2)=N1 HAVJYVTWFMPJBF-VWLOTQADSA-N 0.000 description 1
• BDSRAOKYOPNOIJ-VWLOTQADSA-N ethyl 4-[(2s)-2-[[4-(3-hydroxy-3-methylbut-1-ynyl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C#CC(C)(C)O)=CC(C=2C=CC=CC=2)=N1 BDSRAOKYOPNOIJ-VWLOTQADSA-N 0.000 description 1
• AMIKBVLONDFCNU-NDEPHWFRSA-N ethyl 4-[(2s)-2-[[4-(4-methoxyphenyl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C=2C=CC(OC)=CC=2)=CC(C=2C=CC=CC=2)=N1 AMIKBVLONDFCNU-NDEPHWFRSA-N 0.000 description 1
• BJPCCRKHFCAUHV-VWLOTQADSA-N ethyl 4-[(2s)-2-[[4-(furan-3-yl)-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(C2=COC=C2)=CC(C=2C=CC=CC=2)=N1 BJPCCRKHFCAUHV-VWLOTQADSA-N 0.000 description 1
• FFKHUEJWPZTDAH-DQEYMECFSA-N ethyl 4-[(2s)-2-[[4-[(3s)-3-hydroxypyrrolidin-1-yl]-6-phenylpyridine-2-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2C[C@@H](O)CC2)=CC(C=2C=CC=CC=2)=N1 FFKHUEJWPZTDAH-DQEYMECFSA-N 0.000 description 1
• DXQCQALADMODTQ-NSHDSACASA-N ethyl 4-[(2s)-2-amino-3-[(2-methylpropan-2-yl)oxy]propanoyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(=O)[C@@H](N)COC(C)(C)C)CC1 DXQCQALADMODTQ-NSHDSACASA-N 0.000 description 1
• LVQDMDACCMYMIX-KRWDZBQOSA-N ethyl 4-[(2s)-2-amino-3-[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](N)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 LVQDMDACCMYMIX-KRWDZBQOSA-N 0.000 description 1
• SBXCURMBPFPVRF-VIFPVBQESA-N ethyl 4-[(2s)-2-amino-3-cyanopropanoyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(=O)[C@@H](N)CC#N)CC1 SBXCURMBPFPVRF-VIFPVBQESA-N 0.000 description 1
• SIQIIKXGQXFMMD-ABLWVSNPSA-N ethyl 4-[(2s)-2-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]-3-methylpiperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(=O)[C@@H](N)CCC(=O)OC(C)(C)C)C(C)C1 SIQIIKXGQXFMMD-ABLWVSNPSA-N 0.000 description 1
• JYASQADVXZBDBP-LBPRGKRZSA-N ethyl 4-[(2s)-2-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(=O)[C@@H](N)CCC(=O)OC(C)(C)C)CC1 JYASQADVXZBDBP-LBPRGKRZSA-N 0.000 description 1
• WULQDBJKVIGNNY-SFHVURJKSA-N ethyl 4-[(2s)-3-[(2-methylpropan-2-yl)oxy]-2-(phenylmethoxycarbonylamino)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](COC(C)(C)C)NC(=O)OCC1=CC=CC=C1 WULQDBJKVIGNNY-SFHVURJKSA-N 0.000 description 1
• PJSVCYOLDATRIU-LBPRGKRZSA-N ethyl 4-[(2s)-3-cyano-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(=O)[C@H](CC#N)NC(=O)OC(C)(C)C)CC1 PJSVCYOLDATRIU-LBPRGKRZSA-N 0.000 description 1
• KPWMOVKJWMPHGC-IBGZPJMESA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-(phenylmethoxycarbonylamino)pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 KPWMOVKJWMPHGC-IBGZPJMESA-N 0.000 description 1
• OASGOSNPWXYBNH-DEOSSOPVSA-N ethyl 4-[(2s)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenyl-4-pyrazol-1-ylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C1=CC(N2N=CC=C2)=CC(C=2C=CC=CC=2)=N1 OASGOSNPWXYBNH-DEOSSOPVSA-N 0.000 description 1
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 150000002222 fluorine compounds Chemical class 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 102000043971 human P2RY12 Human genes 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
• UYVXZUTYZGILQG-UHFFFAOYSA-N methoxyboronic acid Chemical compound COB(O)O UYVXZUTYZGILQG-UHFFFAOYSA-N 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• 229950002383 orbofiban Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 238000005897 peptide coupling reaction Methods 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 125000003884 phenylalkyl group Chemical group 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 229910003446 platinum oxide Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960004197 prasugrel Drugs 0.000 description 1
• DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 208000015670 renal artery disease Diseases 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229950005747 sibrafiban Drugs 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical class [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• APCBTRDHCDOPNY-ZETCQYMHSA-N tert-butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)C1 APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 1
• NGIGLOKJPWGIJT-QMMMGPOBSA-N tert-butyl (3s)-3-methoxypyrrolidine-1-carboxylate Chemical compound CO[C@H]1CCN(C(=O)OC(C)(C)C)C1 NGIGLOKJPWGIJT-QMMMGPOBSA-N 0.000 description 1
• SXWAQMMYOHMVSL-NDEPHWFRSA-N tert-butyl 4-[(2s)-2-[(4-chloro-6-phenylpyridine-2-carbonyl)amino]-3-(4-ethoxycarbonylphenyl)propanoyl]piperazine-1-carboxylate Chemical compound C1=CC(C(=O)OCC)=CC=C1C[C@@H](C(=O)N1CCN(CC1)C(=O)OC(C)(C)C)NC(=O)C1=CC(Cl)=CC(C=2C=CC=CC=2)=N1 SXWAQMMYOHMVSL-NDEPHWFRSA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229940125670 thienopyridine Drugs 0.000 description 1
• 239000002175 thienopyridine Substances 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 239000003634 thrombocyte concentrate Substances 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
• 229960002528 ticagrelor Drugs 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960003425 tirofiban Drugs 0.000 description 1
• COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• CICLIHWCPPVFQE-OUTKXMMCSA-N tributyl-[(1r,2s)-2-(methoxymethyl)cyclopropyl]stannane Chemical compound CCCC[Sn](CCCC)(CCCC)[C@@H]1C[C@H]1COC CICLIHWCPPVFQE-OUTKXMMCSA-N 0.000 description 1
• DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 229940019333 vitamin k antagonists Drugs 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1
• 229950004893 xemilofiban Drugs 0.000 description 1